United States: FTC Workshop Signals Continued Focus on Prescription Drug Competition

On November 8, 2017, the US Federal Trade Commission (FTC) hosted a workshop entitled "Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics" to examine the market and economic factors that impact the price of pharmaceuticals, including generic drug competition and supply chain dynamics. The FTC has been particularly aggressive in the prescription drug space in recent years, challenging both mergers that the FTC alleged would substantially lessen competition by eliminating existing and future competition between drug manufacturers, as well as conduct by branded drug manufacturers that the FTC asserts restricts the ability of generic drug manufacturers to compete.1 In addition to these antitrust investigations and enforcement actions, the FTC also develops policy by hosting workshops and requesting public comments, and often uses these opportunities to bring together scholars and practitioners to discuss issues important to its mission of protecting consumers. This workshop signals that parties should expect the FTC to remain active in the pharmaceutical industry during the Trump Administration. However, the FTC may emphasize other methods, such as policy statements or reports, to address what it views as a need both to encourage additional generic drug competition and to reduce the price of pharmaceuticals to consumers generally.

Background

In announcing the workshop, Acting FTC Chairman Maureen K. Ohlhausen noted that "[c]ompetition is key to containing prescription drug costs" and that "it's critical we identify barriers that may prevent drugs from entering the market, even after applicable patent protections have expired." 2 To accomplish this goal, the workshop included speeches from Acting Chairman Ohlhausen and US Food and Drug Commissioner Dr. Scott Gottlieb, as well as panels featuring academics, economists, and industry representatives on generic drug entry and competition, including a discussion of ways to encourage entry and expand access to drugs, as well as panels on the role of intermediaries in the pharmaceutical supply chain (one on pharmacy benefit managers (PBMs) and one on group purchasing organizations (GPOs)).

The FTC's stated purpose for its workshop was to study the barriers to generic drug competition and whether other market forces create inefficiencies that lead to higher drug prices. Acting Chairman Ohlhausen opened the workshop by stating that the Hatch-Waxman Act was enacted to support the broad policy goal of protecting pharmaceutical manufacturers' patent rights in new medicines, which are critical to drive innovation, but also to create legislative incentives to encourage generic drug entry for post-patent pharmaceuticals. This generic drug entry, Acting Chairman Ohlhausen said, causes initial reductions in pharmaceutical prices by twenty to thirty percent and more as additional generic drugs enter the market. The FTC hoped to use the workshop to explore why some markets do not see the same level of generic drug competition when patent protection expires.

Commissioner Gottlieb built on Acting Chairman Ohlhausen's themes and expressed concern about the high costs of life saving medical treatments. He discussed the ways in which the Food and Drug Administration (FDA) has taken steps to encourage generic drug entry, including by expediting the review of the first three generic drug applications where the FDA views competition to be limited, posting a list of off-patent, off-exclusivity products with no approved generic drug offering, hosting its own public meetings to discuss generic drug entry, as well as shortening and streamlining the process for reviewing generic drug applications to reduce review times. Commissioner Gottlieb also expressed concern about what he referred to as the attempts of some "branded firms [to] "game" the system: taking advantage of certain rules, or exploiting loopholes in our system, to delay generic approval" or entering into "restrictive agreements with pharmaceutical supply chain intermediaries[.]"

Fostering Generic Drug Entry

Panelists discussed the benefits of generic drug competition, but identified several dynamics associated with generic drug entry:

  • Patient & Physician Resistance: Many physicians and patients are still resistant to using generic drugs. Panelists attributed this resistance to skepticism regarding the efficacy of generic drugs as well as to promotional efforts by branded manufacturers to encourage use of the branded drug over generics.
  • Unavailability: There may be instances where a generic drug is unavailable in a given market. In some cases, panelists said that a niche patient population may not create enough demand to incentivize generic manufacturers to enter the market. Other challenges that limit the availability of generic drugs could be complex manufacturing processes or shortages of active pharmaceutical ingredients.
  • Consolidation: Panelists also suggested that consolidation among purchasers of generic drugs (i.e., PBMs, wholesalers/distributors, and GPOs) deflates the price of certain generic drugs and has encouraged generic drug manufacturers to exit unprofitable markets. This deflationary pressure allegedly has caused a reduction in generic drug investment and also pushed more manufacturing off shore, which can create vulnerability to supply shortages, quality issues, and the uncertainty of foreign economic policies.
  • Potentially Anticompetitive Conduct: Panelists discussed the steps some branded drug manufacturers allegedly take to limit generic competition, such as: purportedly using allegedly weak or minor patents (such as those related to method of use or release times) to delay generic drug entry; entering into so-called reverse-payment patent settlements, in which value provided by a branded drug manufacturer to the potential generic entrant in the settlement is alleged to have been in exchange for the generic drug manufacturer's agreement to a generic entry date later than would otherwise have occurred; engaging in so-called product hopping, where changes made to an existing product by a branded drug manufacturer are alleged to be for the purpose of transferring patient and prescriber loyalty to a patented product before a generic version of the older product can enter and compete; using the citizen petition process supposedly to delay generic entry rather than raise legitimate safety concern; restricting distribution of the branded drug, e.g., in the case of REMS-restricted drugs, allegedly to deny samples to generic drug manufacturers who may need those samples for bioequivalence testing; and bundling products or offering rebates that violate rules against unlawful exclusive dealing.

Each panelist offered suggestions for how to encourage generic drug entry, but one common theme was to increase antitrust scrutiny to protect against both potentially anticompetitive conduct and market consolidation. Several panelists voiced support for the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act, which would require branded drug manufacturers to share samples of drugs needed for generic drug manufacturers' bioequivalence testing.

The Role of Intermediaries

The next two panels each focused on the role of intermediaries (i.e., PBMs, distributors/wholesalers, and GPOs) in the pharmaceutical supply chain in an attempt to understand the role of those entities and their impact on the price of pharmaceuticals generally. Each panel emphasized the complexity of the pharmaceutical supply chain, and in some cases, panelists stated that complexity may allow supply chain participants to extract profits that cause an increase in the price of pharmaceuticals to consumers.

PBMs

The debate over PBMs focused on two main issues: the impact of rebates to PBMs from drug manufacturers on drug prices and the role PBMs play in pharmacy competition. First, as is at issue in several ongoing lawsuits related to diabetes drugs, the panelists considered whether and how the rebates negotiated between drug manufacturers and PBMs affect the prices paid by ultimate consumers and payors.3 Some panelists argued that a drive for larger rebates pushes up the list price of drugs and that the rebates paid to PBMs add unnecessary costs to the supply chain at the expense of the consumers. Second, a community pharmacist representative suggested that PBMs use their size to take advantage of the complex supply chain and use that supply chain to compete unfairly with independent pharmacists. In response to both of these arguments, a representative of PBMs maintained that PBMs compete fairly, that the complexity of the pharmaceutical supply chain requires the PBM services, which are demanded by their customers, and that rebates have no impact on the prices of pharmaceuticals.

GPOs

The third panel focused on the role of GPOs and discussed the impact of GPOs' compensation structure (in which they are paid by suppliers, rather than members) on the price and quantities available of the products they purchase. GPOs, which leverage purchasing volume to extract lower prices for healthcare products, are often compensated by their suppliers under a commission model, rather than by their members. Panelists contrasted that model with that of distributors/wholesalers, which offer logistical services to drug manufacturers and are compensated on a service fee basis by the manufacturers themselves. Given that distinction, panelists discussed whether the GPO-pricing model has the effect of increasing prices and lowering volumes as GPOs could benefit from higher than competitive pricing. The panel also discussed whether there are alternative models, such as direct buying programs, that could lead to a more efficient distribution system.

Next Steps

The FTC workshop, as intended, raised more questions than it answered, and signaled an ongoing interest in drug competition by both the FTC and FDA. This process will continue as the FTC further studies drug competition and the complex pharmaceutical supply chain, including by accepting public comments on questions related to the topics discussed during the workshop until December 8, 2017. 4

Although no new policy initiatives were announced, the focus of the panels and the topics addressed by the participants indicate that the FTC will continue to enforce the antitrust laws actively in the pharmaceutical industry. Branded drug manufacturers should be mindful of the antitrust laws as they near the loss of patent exclusivity as attempts to extend that exclusivity may be met with FTC review. Generic drug manufacturers may also see increased attention from antitrust authorities who want to ensure there is adequate competition for post-patent drugs.

Notably, the focus on the role of intermediaries in the pharmaceutical supply chain is important for all industry participants and may indicate the likelihood of FTC inquiry into the business dealings of drug manufacturers and both PBMs and GPOs, which have already been the subject of a number of private litigations.

Footnotes

1 See, e.g., In the Matter of Teva Pharmaceutical Industries Ltd. and Allergan PLC, Docket No. C-4589, Complaint (Jul. 27, 2016); See, e.g., FTC v. Actavis, Inc., 133 S. Ct. 2223 (2013); FTC v. Shire ViroPharma Inc., No. 1:17-cv-0013, Complaint for Injunctive and Other Equitable Relief (D. Del. Feb. 7, 2017).

2 Press Release, US Federal Trade Commission, FTC to Conduct Workshop on November 8, Examining Competition Issues Related to Prescription Drug Markets (Oct. 3, 2017).

3 See, e.g., In re Insulin Pricing Litigation, No. 3:17-cv-00699, Complaint (D.N.J. Feb. 2, 2017).

4 Those questions can be found on the FTC website.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement

    Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of www.mondaq.com

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

    Disclaimer

    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

    Registration

    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

    Cookies

    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

    Links

    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

    Mail-A-Friend

    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

    Emails

    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

    Security

    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at enquiries@mondaq.com.

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions